RxDoctor Payments Data

Jennifer Lettsome

Adult Health · Los Angeles, CANPI 1316397896

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Gilead at 52.3% of the total. Among adult health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,987in general payments, 2019–2025

Across 232 payments — averaging $25.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$1K
  • Merck$562
  • GSK$200
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$142
  • Abbott$134
  • plus $687 from 16 others

What the payments were for

  • Food & beverage$5,987100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,987 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.

See all adult health providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala29$115,037
TrulicityDulaglutide42$44,332
JardianceEmpagliflozin32$36,964
OzempicSemaglutide19$18,453
JanuviaSitagliptin Phosphate14$15,586
Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid26$15,556
Tresiba Flextouch U-200Insulin Degludec14$8,696
EliquisApixaban13$7,297
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,063
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,022
Albuterol Sulfate HfaAlbuterol Sulfate52$987
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med26$894
Atorvastatin Calcium171$885
Amlodipine-ValsartanAmlodipine Besylate/Valsartan21$868
Omeprazole73$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$3,129$115,03729 claims
Lilly USA, LLCTrulicity$55$44,33242 claims
Boehringer IngelheimJardiance$17$36,96432 claims
Novo NordiskOzempic$69$18,45319 claims
MerckJanuvia$562$15,58614 claims
PfizerEliquis$20$7,29713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.

Other adult health in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →